Statins, Cholesterol and Cognitive Decline in Alzheimer's
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,000
- 试验地点
- 1
- 主要终点
- Cognitive decline
研究概览
简要总结
Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer's disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through cholesterol metabolism or other mechanisms. The investigators aim to estimate the causal effect of statins on cognitive function measured by MMSE and to identify the mediating or modifying effect of cholesterol between statins and cognitive function in patients with Alzheimer's disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients with AD and mixed dementia registered in SveDem and from SCREAM.
排除标准
- •All patients with a missing MMSE score at diagnosis date will be excluded from the analyses.
- •Patients with at least one measurement of low-density lipoprotein cholesterol (LDL-C) within 1 year before dementia diagnosis.
研究组 & 干预措施
Patients with Alzheimer's disease
Prospective cohort study based on data from the Stockholm Creatinine Measurements (SCREAM) project. Patients diagnosed with AD and mixed dementia and registered in the Swedish Registry for Cognitive/Dementia Diseases are included.
干预措施: STA 4783 (Drug)
结局指标
主要结局
Cognitive decline
时间窗: Through study completion, at least 1 year
The data on cognitive change will be assessed by Mini Mental State Examination (MMSE) score. The MMSE score ranges from 0 and 30. Higher scores mean a better outcome.
次要结局
未报告次要终点
研究者
Sara Garcia-Ptacek
Assistant Professor | Docent
Karolinska Institutet